Skip to search formSkip to main contentSkip to account menu

fosaprepitant

Known as: Fosaprepitantum 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction Fosaprepitant, an intravenous (IV) aprepitant prodrug for chemotherapy-induced nausea and vomiting prophylaxis, is… 
Review
2017
Review
2017
AIMS Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome… 
Highly Cited
2016
Highly Cited
2016
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly… 
Review
2015
Review
2015
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a… 
Review
2013
Review
2013
PurposeThe purpose of this study was to investigate the incidence of fosaprepitant-associated infusion site adverse events (ISAEs… 
Highly Cited
2013
Highly Cited
2013
Background We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and… 
Highly Cited
2011
Highly Cited
2011
PURPOSE Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves… 
Review
2011
Review
2011
PURPOSE To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. METHODS A systematic… 
2011
2011
Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5‐HT3 receptor antagonist, are used to… 
Highly Cited
2007
Highly Cited
2007
Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy‐induced nausea and…